Intellia Therapeutics Earnings
NASDAQ: NTLAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Next earnings date
Thu, Nov 5, 2026
Fiscal period
Sep/2026
EPS estimate
$-0.82
Intellia Therapeutics earnings summary
Intellia Therapeutics is scheduled to report Sep/2026 earnings on Nov 5, 2026, with analysts expecting EPS of $-0.82. In its most recent report on Aug 6, 2026 (Q2 2026), NTLA posted EPS of $-0.80. Revenue for the quarter was $7.7 million.
Across the last 16 reports, NTLA shares moved an average of 7.7% (in either direction) in the first trading session after results, rising 9 times and falling 7 times.
Summary generated from market data by MetaCap's automated system. Methodology
NTLA earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 6, 2026 | — | $-0.80 | — | -0.3% |
| May 11, 2026 | — | $-0.81 | — | -7.8% |
| Feb 26, 2026 | — | $-0.81 | — | -2.5% |
| Nov 6, 2025 | — | $-0.92 | — | -8.6% |
| Aug 7, 2025 | — | $-0.98 | — | +1.9% |
| May 8, 2025 | — | $-1.10 | — | +4.7% |
| Feb 27, 2025 | — | $-1.27 | — | +2.6% |
| Nov 7, 2024 | — | $-1.34 | — | -16.5% |
| Aug 8, 2024 | — | $-1.52 | — | +5.5% |
| May 9, 2024 | — | $-1.12 | — | +7.2% |
| Feb 22, 2024 | — | $-1.47 | — | +25.1% |
| Nov 9, 2023 | — | $-1.38 | — | +16.5% |
| Aug 3, 2023 | — | $-1.40 | — | -0.3% |
| May 4, 2023 | — | $-1.17 | — | -1.3% |
| Feb 23, 2023 | — | $-1.38 | — | +15.0% |
| Nov 3, 2022 | — | $-1.49 | — | +7.9% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.